Holen Sie sich die Stockscreener-App
2.59
4.03%
-0.14
Handel nachbörslich:
2.69
0.10
+3.86%
Schlusskurs vom Vortag:
$2.73
Offen:
$2.82
24-Stunden-Volumen:
429.83K
Relative Volume:
0.08
Marktkapitalisierung:
$39.16M
Einnahmen:
$2.09M
Nettoeinkommen (Verlust:
$-30.04M
KGV:
-0.7924
EPS:
-3.2685
Netto-Cashflow:
$-27.57M
1W Leistung:
-8.39%
1M Leistung:
-14.94%
6M Leistung:
-42.29%
1J Leistung:
-74.11%
1-Tages-Spanne:
$2.55
$2.82
1-Wochen-Bereich:
$2.55
$3.20
52-Wochen-Spanne:
$2.13
$11.25
Cervomed Inc Stock (CRVO) Company Profile
Firmenname
Cervomed Inc
Sektor
Branche
Telefon
(617) 744-4400
Adresse
20 PARK PLAZA, BOSTON
Compare CRVO vs VRTX, REGN, ARGX, RVMD, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CRVO
Cervomed Inc
|
2.59 | 41.28M | 2.09M | -30.04M | -27.57M | -3.2685 |
VRTX
Vertex Pharmaceuticals Inc
|
515.57 | 128.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
805.86 | 82.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
986.80 | 53.26B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
211.94 | 43.66B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
362.66 | 39.31B | 5.76B | 514.49M | 1.10B | 4.4813 |
Cervomed Inc Stock (CRVO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-18 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-03-13 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
| 2024-12-17 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2024-12-11 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2024-12-11 | Herabstufung | Morgan Stanley | Overweight → Underweight |
| 2024-12-10 | Herabstufung | D. Boral Capital | Buy → Hold |
| 2024-12-06 | Eingeleitet | ROTH MKM | Buy |
| 2024-12-05 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-09-18 | Eingeleitet | Chardan Capital Markets | Buy |
| 2024-07-26 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-02-15 | Eingeleitet | Canaccord Genuity | Buy |
| 2020-11-17 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2018-03-21 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Cervomed Inc Aktie (CRVO) Neueste Nachrichten
SABBY MANAGEMENT, LLC's CervoMed Inc(CRVO) Holding History - GuruFocus
CRVO Stock Rockets Nearly 100% On Patent Win Before Offering News Cools Rally - Stocktwits
CervoMed (CRVO): RA Capital discloses 8.6% stake through 1.27M warrant shares - Stock Titan
CervoMed (CRVO) holders CVI and Heights report 0% stake in amended filing - Stock Titan
Woodline Partners (CRVO) discloses 5.1% beneficial stake in CervoMed common stock - Stock Titan
Armistice Capital discloses 9.53% CervoMed (CRVO) ownership via Master Fund - Stock Titan
CRVO Reiterates by HC Wainwright & Co. -- Price Target Maintained at $25 - GuruFocus
CCORF Maintains CervoMed(CRVO.US) With Buy Rating, Maintains Target Price $18 - Moomoo
CervoMed at Canaccord Genuity conference: dLB push gains ground By Investing.com - Investing.com Canada
CRVO: Phase III-ready DLB drug shows strong clinical data; pipeline expands into PPA and ALS - TradingView
JonesTrading Maintains CervoMed(CRVO.US) With Buy Rating, Cuts Target Price to $12 - Moomoo
CervoMed reports Q2 2026: $24.9M cash position, net loss $6.6M; advancing neflamapimod toward Phase 3 - TradingView
CervoMed (NASDAQ: CRVO) details Q2 2026 loss, cash runway and DLB program - Stock Titan
Canaccord cuts CervoMed stock price target on funding uncertainty By Investing.com - Investing.com India
CRVO Maintained by Canaccord Genuity -- Price Target Lowered to $18 - GuruFocus
CervoMed Q2 Results: EPS Misses Estimate, Losses Widen YoY - scanx.trade
CervoMed Q2 Results: Net Loss Widens To $6.6M, Seeks DLB Partner - scanx.trade
Canaccord cuts CervoMed stock price target on funding uncertainty - Investing.com
CervoMed Reports Second Quarter 2026 Financial Results and Provides Corporate Updates - manilatimes.net
CervoMed Q2 net loss lower than estimates as costs drop - TradingView
CCORF Maintains CervoMed(CRVO.US) With Buy Rating, Cuts Target Price to $18 - Moomoo
CRVO Q2'26 Earnings: revenue estimate is 50.00K USD - TradingView
CERVOMED INC : CANACCORD GENUITY CUTS TARGET PRICE TO $18 FROM $27 - Bitget
CervoMed Inc reports results for the quarter ended June 30Earnings Summary - TradingView
CervoMed Inc. 2026: Revenue $0 Net income ($6.57M), EPS ($0.64) — 10-Q Summary - TradingView
CRVO: Raised $20.5M in June 2026 to fund R&D and strategic partnership for Phase 3 DLB trial - TradingView
CervoMed (NASDAQ: CRVO) raises $20.5M, ends Q2 with $24.9M cash - Stock Titan
CRVO: Neflamapimod progresses to Phase 3 for DLB, with strong cash position and key milestones ahead - TradingView
CervoMed Inc (CRVO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
CervoMed Inc. (CRVO) Edges Lower to $2.77 as Shares Consolidate Within Tight Trading RangeADD Alert - dars.gov.et
CervoMed to Participate in Fireside Chat to Highlight Recent Progress in the Neflamapimod Clinical Development Program at the Canaccord Genuity 46th Annual Growth Conference - manilatimes.net
CervoMed to discuss neflamapimod progress at Ca... - Pluang
CervoMed Inc expected to post a loss of 87 cents a shareEarnings Preview - TradingView
CervoMed granted UK Innovation Passport for neflamapimod in dementia with Lewy bodies - TradingView
CervoMed Announces Neflamapimod Awarded Innovation Passport Designation Under the UK Innovative Licensing and Access Pathway (ILAP) for Treatment of Dementia with Lewy Bodies (DLB) - manilatimes.net
CervoMed's neflamapimod wins UK ILAP Innovation Passport for DLB - scanx.trade
CervoMed Inc (CRVO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
CervoMed Inc (CRVO) Cash Flow - TradingKey
CervoMed Inc (CRVO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
CervoMed Inc (CRVO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
CRVO|CervoMed Inc|Price:2.690|Chg%:+0.030 - TradingKey
CRVO|CervoMed Inc|Price:2.640|Chg%:-0.020 - TradingKey
CervoMed Inc (CRVO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
CervoMed Inc (CRVO) Valuation: PE, PB & Fair Value Analysis - TradingKey
CervoMed Inc (CRVO) Institutional Confidence - TradingKey
CervoMed Inc (CRVO) Income Statement - TradingKey
CervoMed Inc. Revenue Breakdown – NASDAQ:CRVO - TradingView
CRVO|CervoMed Inc|Price:2.660|Chg%:-0.010 - TradingKey
CervoMed Inc. (CRVO) Q1 2026 Earnings: EPS Misses Estimates as Clinical Investment ContinuesEarnings Acceleration Picks - dars.gov.et
Matt Winton Says Most Biotechs Are Not the Best to Launch Their Own Drugs — and That’s a Strength, Not a Failure - finance.biggo.com
Insiders the Biggest Winners as CervoMed Inc.'s (NASDAQ:CRVO) Market Cap Rises to US$151m - 富途牛牛
Finanzdaten der Cervomed Inc-Aktie (CRVO)
Umsatz
Nettogewinn
Free Cashflow
ENV
Cervomed Inc-Aktie (CRVO) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Winton Matthew | Chief Commercial and Business |
Nov 17 '25 |
Buy |
8.43 |
3,500 |
29,505 |
13,500 |
| Winton Matthew | Chief Commercial and Business |
Nov 18 '25 |
Buy |
7.95 |
1,500 |
11,925 |
15,000 |
| Gregoire Sylvie | Director |
Nov 17 '25 |
Buy |
8.46 |
10,807 |
91,427 |
12,500 |
| Gregoire Sylvie | Director |
Nov 17 '25 |
Buy |
8.46 |
10,793 |
91,309 |
1,484,078 |
| ELDER WILLIAM ROBERT | CFO, GC & Secretary |
Nov 18 '25 |
Buy |
8.32 |
2,500 |
20,800 |
12,500 |
| ELDER WILLIAM ROBERT | CFO, GC & Secretary |
Nov 17 '25 |
Buy |
8.45 |
1,000 |
8,450 |
10,000 |
| ALAM JOHN J | CEO & President |
Nov 17 '25 |
Buy |
8.46 |
10,807 |
91,427 |
1,484,078 |
| ALAM JOHN J | CEO & President |
Nov 17 '25 |
Buy |
8.46 |
10,793 |
91,309 |
12,500 |
| Gregoire Sylvie | Director |
Nov 13 '25 |
Buy |
7.51 |
4,447 |
33,397 |
1,471,578 |
| Gregoire Sylvie | Director |
Nov 14 '25 |
Buy |
7.57 |
1,707 |
12,922 |
1,473,285 |
2.20%
0.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):